Uterine adenomyosis is a benign disorder that often co-occurs with endometriosis and/or leiomyoma, and impairs quality of life. The genomic features of adenomyosis are unknown. Here we apply next-generation sequencing to adenomyosis (70 individuals and 192 multiregional samples), as well as co-occurring leiomyoma and endometriosis, and find recurring KRAS mutations in 26/70 (37.1%) of adenomyosis cases. Multi-regional sequencing reveals oligoclonality in adenomyosis, with some mutations also detected in normal endometrium and/or co-occurring endometriosis. KRAS mutations are more frequent in cases of adenomyosis with co-occurring endometriosis, low progesterone receptor (PR) expression, or progestin (dienogest; DNG) pretreatment. DNG's anti-proliferative effect is diminished via epigenetic silencing of PR in immortalized cells with mutant KRAS. Our genomic analyses suggest that adenomyotic lesions frequently contain KRAS mutations that may reduce DNG efficacy, and that adenomyosis and endometriosis may share molecular etiology, explaining their co-occurrence. These findings could lead to genetically guided therapy and/or relapse risk assessment after uterine-sparing surgery.
U terine adenomyosis is a benign condition in which endometrium-like epithelial and stromal tissues appear in the myometrium, surrounded by hypertrophic smooth muscle. Similar to endometriosis and leiomyoma, adenomyosis is common in women of reproductive age 1, 2 . Adenomyosis and endometriosis are closely linked diseases, as both are estrogendependent and often co-exist in the same patients [3] [4] [5] . This cooccurrence is a risk factor for relapse in women who have undergone fertility sparing surgery [6] [7] [8] .
Although adenomyosis and endometriosis share some histological features and molecular changes 9 , there are notable differences in their pathogenesis, lesion localization, and clinical features 10, 11 . For example, menorrhagia, recurrent implantation failure, and pregnancy loss are frequent in adenomyosis but not in endometriosis 12, 13 . In addition, multiparity and prior uterine surgeries are linked to adenomyosis but not to endometriosis 14 . Thus, adenomyosis has come to be recognized as a distinct clinical entity.
The etiology of adenomyosis is currently unknown. Several theories for its development have been proposed, including direct invasion of endometriotic cells or an endometriotic lesion, metaplasia of displaced embryonic pluripotent Mullerian remnants, and differentiation of endometrial stem/progenitor cells 5, 15 . In addition, despite the known differences between endometriosis and adenomyosis, Koninckx et al. 9 hypothesized in a recent review that a common molecular mechanism might underlie the pathogenesis of these disorders. However, no direct evidence to support this hypothesis exists at present, due to a lack of knowledge on the molecular mechanisms underlying adenomyosis pathogenesis.
The growth of an adenomyotic lesion is generally enhanced by estrogen and abrogated by progestogens. Adenomyotic symptoms are currently relieved using either endocrine therapies based on gonadotrophin-releasing hormone agonist (GnRHa) or progestins such as dienogest (DNG), or by employing a levonorgestrel-releasing intrauterine system (LNG-IUS) 16, 17 . However, no formal guidelines for best medical management using these hormonal therapies exist 16 . Identification of the molecular underpinnings of adenomyosis could offer opportunities for precision treatment of this condition.
Next-generation sequencing (NGS) is a powerful tool that permits the identification of somatic genomic alterations. Whereas mutations in MED12 are frequent in leiomyoma (~70%) 18 , recurrent mutations in cancer-associated genes such as KRAS, PIK3CA, ARID1A, PPP2R1A, PTEN, and/or TP53 occur in uterine endometrial carcinoma 19 . Similarly, anatomical subtypes of endometriosis, such as ovarian endometrioma (EN-OV) and deep infiltrating (EN-DI) endometriosis, harbor mutations in PIK3CA, ARID1A, PPP2R1A, and/or KRAS 20, 21 . Importantly, PIK3CA-or KRAS-mutated clones arising in histologically normal uterine endometrium have been proposed as the cellular origin of endometriosis 21 . However, very recent genomic analyses of normal human tissues, including endometrium, have undermined this hypothesis. RNA-sequencing analyses of 29 types of normal tissues, including the uterus, have uncovered the presence of expanded clones of cells with relatively high mutation burdens in many normal tissues 22 . Furthermore, endometrium samples from individuals who have undergone endometrial biopsy for a reason unrelated to endometriosis have frequently shown KRAS and PIK3CA mutations 23, 24 . Thus, endometrial clones bearing KRAS and/or PIK3CA mutations may not necessarily drive the pathogenesis of endometriosis. Ideally, the status of KRAS-and/or PIK3CA-mutated clones in histologically normal endometrium (NE) should be compared between individuals with and without endometriosis. Accordingly, the exact contribution of KRAS and PIK3CA mutations to endometriosis remains unresolved.
In contrast to endometriosis, there has been, to date, no parallel genomic analysis of adenomyosis. Therefore, it is unknown whether adenomyosis involves clonal proliferation and whether its mode of molecular pathogenesis is shared with other gynecological disorders. This highlights the need for a comprehensive genomic characterization of adenomyosis to provide insights into many important and unresolved questions in adenomyosis etiology and pathology. To address this knowledge gap, we conduct NGS on a large panel of adenomyosis and co-occurring leiomyoma and endometriosis tissues. Our analyses reveal the presence of oligoclonality and recurrent KRAS mutations in adenomyosis tissues, and suggest that adenomyosis and endometriosis share molecular etiology, which may explain their frequent co-occurrence. Furthermore, we provide functional evidence for the role of mutant KRAS in mediating the efficacy of DNG as an adenomyosis therapy. Importantly, our findings could inform relapse risk assessment and therapeutic strategies for adenomyosis patients.
Results
Somatic mutations are present in adenomyosis. To define the molecular pathology of adenomyosis, we used NGS to characterize its genomic landscape. We collected fresh-frozen samples from 70 individuals: a discovery cohort of 51 adenomyosis patients whose samples were subjected to whole exome sequencing (WES), plus an additional 19 individuals who were biopsied at a later time and whose samples were subjected to targeted deep sequencing (TDS) (Supplementary Data 1 and 2). In 29 of these 70 individuals, multi-regional sampling of adenomyosis with/ without co-existing endometriosis and leiomyoma was performed and adjacent normal tissues were collected (Supplementary Fig. 1 and Supplementary Data 3). In total, we banked fresh-frozen lesions of adenomyosis (192 specimens from 70 individuals), endometriosis (15 specimens from 10 individuals), leiomyoma (13 specimens from 10 individuals), ovarian cancer (5 specimens from 5 individuals), adjacent normal myometrial tissues (13 specimens from 12 individuals), and adjacent normal endometrial tissues (8 specimens from 6 individuals). As germline controls, we collected fresh-frozen peripheral blood or mononuclear cells from ascites (70 specimens from 70 individuals) (Supplementary Data 3). WES was performed on these samples with coverage of 130-170× for adenomyosis, endometriosis, leiomyoma, and ovarian cancer, and~100× for adjacent and normal tissue samples ( Supplementary Fig. 2 and Supplementary Data 4). Our robust criteria and validation by TDS (see Methods, Supplementary Fig. 3 , and Supplementary Data 5) permitted us to detect 134 unique synonymous and non-synonymous single-nucleotide variations (SNVs) in 31/51 (60.8%) adenomyosis cases (Supplementary Data 6), raising the possibility that adenomyosis is a clonal disorder with somatic mutations. These adenomyosis SNVs were present in low numbers (mean of 2.6 mutations/ individual) and at low variant allele frequencies (VAF) (mean 4.8%; range 2.47-16.02%). These VAF values are comparable to those in co-occurring endometriosis but much lower than those in co-occurring leiomyoma and ovarian cancer ( Fig. 1a, KRAS is recurrently mutated in adenomyosis. Analysis of the SNVs in adenomyosis cases revealed recurrent mutations encoding oncogenic KRAS p.G12 alterations (Patients #2, #3, and #6 in Supplementary Data 6). Patient #2 also harbored a mutation encoding the PPP2R1A p.R179 alteration observed in endometrial cancer and endometriosis. However, other mutations associated with uterine endometrial carcinoma and/or endometriosis (e.g., PIK3CA, ARID1A, PTEN, and TP53) [19] [20] [21] were not identified in adenomyosis using our SNV criteria (Supplementary Data 6). We speculated that, confined by our criteria (mutant read number <8) ( Supplementary Fig. 3 ), our WES coverage may not have been deep enough to detect alterations in these genes that had low VAF due to either minimal content or limited expansion of mutated adenomyosis clones. To sharpen our analysis, we examined the ClinVar database (https://www.ncbi.nlm. nih.gov/clinvar/), a public database of pathogenic gene variations, to determine whether any registered pathogenic/driver mutations of KRAS, PIK3CA, PPP2R1A, ARID1A, PTEN, and/or TP53 were detectable in our adenomyosis WES data, including in the small number of mutant reads that had been filtered out by our SNV criteria. Using this strategy, we identified low numbers (<4) of pathogenic mutations of KRAS, PIK3CA, PPP2R1A, ARID1A, TP53, and PTEN in adenomyosis samples (Supplementary Data 10). To explore whether these candidate mutations were O v a r i a n c a n c e r O v a r i a n c a n c e r 
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NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-13708-y ARTICLE truly SNVs or pseudo-positives, we performed TDS on the adenomyotic lesions as well as on the corresponding germline control samples wherever possible. Although no mutation candidates in ARID1A, TP53, or PTEN were validated as somatic mutations in adenomyosis (Supplementary Data 11), this TDS analysis revealed recurrent somatic pathogenic mutations of KRAS and PIK3CA in this disease (Supplementary Data 12). We next applied TDS analysis of KRAS, PIK3CA, and PPP2R1A to not only the discovery cohort (n = 51; Fig. 1c , pink sequencing column) but also to the additional 19 adenomyosis patients ( Fig. 1c , yellow sequencing column). Recurrent somatic pathogenic KRAS mutations, including 25 cases of alterations at G12 and 1 case at Q61, were identified in 37.1% (26/70) of adenomyosis cases (Figs. 1c, f, g and Supplementary Data 12). Somatic mutations encoding the PIK3CA p.H1047 alteration were validated in lesions from Patients #1 and #27, as was a mutation encoding PPP2R1A p.P179 in a lesion from Patient #2 ( Fig. 1c and Supplementary Data 12). Based on these findings, we hypothesized that somatic KRAS mutation might be an important genomic alteration associated with adenomyosis. Consistent with published data 18, 20, 21 , samples of co-occurring endometriosis in some of our adenomyosis patients bore both KRAS and PIK3CA mutations ( Fig. 1d and Supplementary Data 12), whereas most co-occurring leiomyoma samples harbored MED12 mutations ( Fig. 1e ). Thus, the profiles of the dominant mutations linked to these three benign gynecological disorders differ.
Mutations in the epithelial cell component of adenomyosis.
Only a minor fraction of an adenomyosis lesion comprised epithelial cells ( Fig. 2a ). This observation prompted us to consider whether the low VAFs we observed were due to low epithelial component content or limited clonal expansion of mutated cells. To isolate the epithelial component of adenomyosis samples, we performed laser capture microdissection (LCM) on formalinfixed paraffin-embedded (FFPE) tissue samples from Patients #2, #6, and #8 ( Fig. 2b-e ). We isolated genomic DNA from epithelial cells of adenomyosis tissue (LCM-A), as well as from adjacent muscle cells (non-diseased control; LCM-ADJ), and performed TDS. Compared with bulk frozen samples, VAFs were markedly increased in LCM-A (but not LCM-ADJ) samples from all three adenomyosis cases ( Fig. 2c -e, Supplementary Fig. 6 , and Supplementary Data 13), demonstrating that the low VAFs detected in our WES analyses of bulk frozen adenomyosis lesions were due to low epithelial component content rather than to poor expansion of mutated adenomyosis clones. These LCM experiments indicate that somatic mutation occurs in the epithelial component of adenomyosis, and that adenomyosis may thus arise from the ectopic proliferation of mutated epithelial cell clones.
Adenomyosis is clonally diverse and distinct from leiomyoma. To initiate our investigation of clonal diversity within adenomyosis lesions, we performed multi-regional sampling and TDS of adenomyosis and co-existing leiomyoma lesions from Patients #28, #29, and #5. We detected multiple mutations in each lesion ( Fig. 3 , Supplementary Figs. 7-9, and Supplementary Data [14] [15] [16] . Some mutations were shared among almost all multi-regional samples from a single patient (e.g., ZNF672 in Patient #28 (Fig. 3a ); C1QTNF and MSS51 in Patient #29 (Fig. 3b) ), suggesting that these genetic alterations were acquired early during adenomyosis development, whereas other mutations were more restricted ( Fig. 3 ). Most mutations detected in adenomyosis and co-existing leiomyoma were mutually exclusive (Figs. 3b, c and 4a, and Supplementary Data 15-17), implying the lack of a clonal relationship between these disorders. Thus, despite their frequent co-occurrence, adenomyosis and leiomyoma are distinct entities.
KRAS-mutated clones in adenomyosis occur in normal tissues.
To investigate whether the genomic alterations in adenomyosis originate in histologically NE and/or myometrium (NM), we compared mutations detected by TDS in multi-regional adenomyosis samples with those in adjacent NE/NM tissues ( Fig. 4a- . Most mutations were detected only in adenomyotic lesions but some, including those of KRAS and PIK3CA, also appeared in NE (e.g., SERPINA in Fig. 4a , PIK3CA in Fig. 4b , and KRAS in Fig. 4a , c). Thus, these mutations likely arose in NE cells before they invaded the NM, consistent with a previously proposed etiology of endometriosis 21 . However, although adenomyosis frequently co-occurs with endometriosis, to date there has been no molecular evidence to support a common cellular origin. Significantly, we found identical KRAS mutations in co-existing adenomyotic and endometriotic lesions in multiple patients ( Fig. 4d -i, Supplementary Figs. 13 and 14, and Supplementary Data 20 and 21). These results are in line with the frequent co-occurrence of endometriosis anatomical subtypes, such as EN-OV (p = 0.001; Table 1 ) and EN-DI (p = 0.0319; Table 1 ), in our cohort of KRAS-mutated adenomyosis patients ( Table 1 and Supplementary Data 22) . Our data collectively raise the possibility that KRAS-mutated clones arising in NE acquire enhanced invasiveness and proliferative capacity that enable them to grow ectopically, driving adenomyosis.
KRAS-mutated clones in normal tissue may lead to adenomyosis. As noted above, recent reports have revealed frequent KRAS and PIK3CA mutations in NE, i.e., in uterine endometrium that are histologically normal and unaffected by endometriosis or adenomyosis 23, 24 . We also detected these mutations in NE adjacent to adenomyotic lesions, prompting us to investigate the relevance of KRAS-and PIK3CA-mutated clones to the molecular pathogenesis of adenomyosis. To this end, we examined whether the frequency of these mutations was altered in NE adjacent to an adenomyotic lesion. We collected either freshfrozen or FFPE samples of uterine tissue from 56 individuals: 18 individuals with adenomyosis (group A), 14 individuals with endometriosis but not adenomyosis (group E), and 24 individuals with neither endometriosis nor adenomyosis (group Non-A/E) (Supplementary Data 23 and 24). After enrichment by macro- Fig. 1 Number and allele frequency of single-nucleotide variations (SNVs) identified in adenomyosis and co-occurring lesions. a Number of somatic mutations in samples of adenomyosis (n = 51) and co-occurring cases of endometriosis (n = 7), leiomyoma (n = 8), and ovarian cancer (n = 5) presented as Tukey's Box-and-Whisker plots. b Variant allele frequency (VAF) identified in the adenomyosis and co-occurring endometriosis, leiomyoma, and ovarian cancer samples in a presented as Tukey's Box-and-Whisker plots. c-e Recurrence of the indicated gene mutations in adenomyosis (c), co-occurring endometriosis (d), and co-occurring leiomyoma (e). Top boxes: each box represents an individual SNV that was identified by whole exome sequencing (WES). SNVs were validated (grey) or not (white) by targeted deep sequencing (TDS). Middle boxes: samples were subjected to WES (purple) or TDS (yellow). Adenomyosis patients with co-occurring endometriosis (blue), leiomyoma (orange), and/or ovarian cancer (purple), and low progesterone receptor (PR) expression (black) are indicated above the patient number. Bottom boxes: each box represents an individual mutation of KRAS (red), PIK3CA (turquoise), PPP2R1A (blue), or MED12 (brown). f VAF values for KRAS mutations in adenomyosis lesions (blue) or peripheral blood (red) as determined by TDS. g Schematic representation of somatic mutations in KRAS.
dissection, samples of NE and adjacent NM (control) for each individual were subjected to TDS, to assess KRAS, PIK3CA, and PPP2R1A status ( Fig. 5 ). Among macro-dissected NE samples, KRAS mutations were commonly observed in group A (10/18 = 55.6%) and group E (7/14 = 50%), but less frequently in group Non-A/E (7/24 = 29.1%) ( Fig. 5a and Supplementary Data 24-26) as determined by our mutation criteria (see Methods). Mutations in PIK3CA were also observed but to a lesser extent: group A (2/18 = 11.1%), group E (5/14 = 35.7%), and group Non-A/E (6/24 = 25%) ( Fig. 5a and Supplementary Data 23-25). These observations are consistent with recent publications showing that recurrent KRAS and PIK3CA mutations can occur in the endometrium that appears to be histologically normal 23, 24 . Next, we compared the VAFs of KRAS, PIK3CA and PPP2R1A hotspot mutations in the macro-dissected NE of group A vs. group E vs. group Non-A/E ( Fig. 5b and Supplementary Data 26). Importantly, the VAFs of mutations encoding oncogenic KRAS p. G12/G13 alterations (but no other mutations) were significantly enhanced in group A (mean value: 1.641%) compared with group Non-A/E (0.301%) (p = 0.008; Fig. 5b and Supplementary Data 26), suggesting that KRAS-mutated clones had expanded in NE of individuals with adenomyosis. We found that KRAS mutations were not significantly more frequent in samples from group A (p = 0.117) and group E (p = 0.297) than in those from group Non-A/E (Fig. 5a ). However, our VAF analysis revealed a statistically significant increase in KRAS-mutated clones in group A compared with group Non-A/E (p = 0.008) ( Fig. 5b ). Follow-up in a suitably large number of additional patient samples is required, but if corroborated, the latter result suggests our hypothesis that an increase in the frequency of KRAS-mutated clones in NE might be the origin of adenomyosis. Taken together, these genomic analyses of NE suggest that an increase in expanded KRAS-mutated clones in this tissue may be an early step in the molecular pathogenesis of adenomyosis.
KRAS mutations reduce DNG efficacy by PR silencing. Many adenomyotic patients initially receive hormonal treatment, including administration of the PR agonist DNG 17, 25 . Those patients who do not respond to such hormonal treatment then undergo surgery. Our analyses revealed intriguing clinical differences between cases of adenomyosis with KRAS mutations vs. those without. Specifically, KRAS mutations were more frequent in lesions of patients who had been pretreated with DNG (84% (11/13)) compared with non-pretreated patients (26% (15/57); p = 0.0002), a difference not found in patients treated with GnRHa (Table 1 and Supplementary Data 22). This observation generates two hypotheses as follows: (1) DNG may be less efficacious in patients bearing KRAS-mutated adenomyotic clones, allowing these abnormal cells to persist until surgery; and (2) DNG treatment drives an enrichment of KRAS mutations in adenomyosis. We next sought to distinguish between these two possibilities. DNG reportedly exerts an anti-proliferative effect on cells of the epithelial component of adenomyosis 26 . We examined the effect of mutated KRAS expression on DNG's ability to suppress proliferation by taking advantage of an immortalized uterine endometrial epithelial cell line. We engineered these cells to overexpress wild type KRAS (KRAS-WT), mutated KRAS (KRAS-Mut; G12C or G12D), PIK3CA-WT, or mutated PIK3CA (PIK3CA-Mut; E545K or H1047R), and then assessed their viability and proliferation following exposure to DNG ( Fig. 6a-c) . We observed that a greater percentage of DNG-treated immortalized endometrial cells expressing KRAS-Mut were viable compared to empty vector-transfected controls (Fig. 6b ). Furthermore, analysis of BrdU incorporation showed that KRAS-Mut expression abrogated DNG's ability to suppress cell proliferation ( Fig. 6c ). In contrast, expression of mutated PIK3CA in immortalized cells had no effect on DNG efficacy (Fig. 6b, c) . Thus, expression of mutated KRAS interferes with DNG's ability to reduce cell proliferation. Taken together, these data support our hypothesis #1 (KRAS-mutated adenomyotic clones are less sensitive to DNG treatment) rather than hypothesis #2 (DNG drives KRAS mutations in adenomyosis patients). However, it should be noted that future follow-up studies using an appropriately sized cohort will be necessary to reach a definitive conclusion. NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-13708-y ARTICLE DNG is a PR agonist, which prompted us to examine PR protein levels in KRAS-mutated adenomyosis. We performed immunohistochemical analyses to estimate PR protein levels in the epithelial component of adenomyosis lesions from all 70 of our adenomyosis patients ( Fig. 7 , Table 1 , and Supplementary Data 22) . A decrease in PR protein specifically in the epithelial component was significantly more frequent in samples from patients with KRAS-Mut (13/26; 50%) than in samples from patients with KRAS-WT (7/44; 15.91%) (p = 0.052; Table 1 ). Strikingly, these findings recapitulate those reported for endometrial cancer 27 .
There are two major PR isoforms, PR-A and PR-B, which are transcribed from different promoters in a single gene 28 . To investigate whether the reduced PR protein in KRAS-mutated adenomyosis samples was due to an effect of mutant KRAS on PR mRNA expression, we applied qPCR analysis to our immortalized endometrial cells overexpressing KRAS-Mut, KRAS-WT, PIK3CA-WT, or PIK3CA-Mut (please see the Source Data file). We found that PR-A/B mRNAs were indeed downregulated in cells expressing KRAS-Mut but not in those expressing KRAS-WT, PIK3CA-WT, or PIK3CA-Mut (Fig. 6d ). Although these in vitro overexpression data derived from a single cell line do not show whether KRAS mutation downregulates PR mRNA directly or indirectly, they suggest that KRAS-Mut is linked to downregulation of PR expression. Further experiments employing additional independent cell lines and/or patient-derived primary cultures should be conducted in the future to validate these results.
Lastly, we sought to determine how PR downregulation by KRAS-Mut might be achieved. Expression of PR-A/B is known to be regulated, at least in part, by methylation of the PR gene promoters [28] [29] [30] . In endometriosis, epigenetic silencing of PR-A/B imposed by increased methylation of CpG islands within exon 1 has been observed 29 . To investigate whether increased DNA methylation was involved in downregulating PR in KRAS-Mut adenomyosis, we performed bisulfite sequencing of DNA from the enriched epithelial component of adenomyotic lesions from PR-expressing KRAS-WT samples (n = 20) and from all 13 PRnegative KRAS-Mut samples. In PR-expressing KRAS-WT adenomyosis, no significant DNA methylation of CpG islands in the PR-A/B promoters was detected ( Fig. 8 and Supplementary Data 27) . In contrast, there was a marked increase in the methylation level of the PR-A/B promoters in KRAS-Mut adenomyosis. These results suggest that epigenetic silencing may contribute to the PR downregulation observed in KRASmutated adenomyosis, and that DNG may be less effective in treating KRAS-mutated adenomyosis due to this suppression of PR-A/B expression.
Discussion
Our NGS-based study provides fresh insights into the pathogenesis of adenomyosis. We have shown that: (i) KRAS-mutated adenomyotic clones originate from NE (Fig. 4a-c) ; (ii) KRAS mutations are shared by co-occurring adenomyosis and endometriosis lesions ( Fig. 4d-i) ; and (iii) the presence of KRAS mutations in adenomyosis is associated with the co-occurrence of endometriosis (Table 1 and Supplementary Data 22) . Although inflammation caused by ectopic proliferation of epithelial cells and/or de novo metaplasia may play a role in the genetic alterations and disease pathogenesis in some adenomyosis patients, our data suggest that both adenomyotic and endometriotic clones can arise from NE, explaining the high frequency of co-occurrence of these disorders. Nevertheless, we did find evidence of clonal heterogeneity in their development. In Patients #6 and #24, the adenomyotic and endometriotic lesions contained different KRAS mutations (Figs. 4f, Recent genomic analyses have shown that histologically NE can bear a relatively high burden of mutations that includes recurrent PIK3CA and KRAS alterations 23, 24 . Consistent with these observations, we also detected recurrent PIK3CA and KRAS mutations in individuals without adenomyosis or endometriosis (Fig. 5a ). However, the frequency and VAF of such mutated clones were significantly elevated in adenomyosis samples (Fig. 5b) , suggesting that additional alterations in KRAS-mutated clones in the NE might occur very early during the molecular pathogenesis of adenomyosis. Although our study did not definitively identify a common or first event of genetic and/or epigenetic alteration establishing NE clonality, from a mechanistic point of view, KRAS or PIK3CA mutation would be considered likely to provide NE cell clones with the ability to proliferate and invade neighboring NM and/or other organs, driving the development of adenomyosis. Mutations of MED12 and/or FH, which are common in leiomyoma and show high VAFs, have been reported in~10% of adenomyosis and adenomyotic polyps 31, 32 . However, for unknown reasons, these alterations were not detected in our NGS analyses of our adenomyosis cohort (Supplementary Data 6 and 15-17). Lastly, the burdens of total and cancer-associated mutations are known to become elevated in NE by ageing and high NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-13708-y ARTICLE body mass index 24 . Although age did not correlate with frequency of KRAS mutations in our cohort ( Supplementary Data 25) , it would be intriguing to determine whether these factors are also relevant in the contexts of adenomyosis and endometriosis, a question demanding future studies using a larger patient cohort. Relapses of endometriosis and adenomyosis are relatively common 6,33 and co-existence of adenomyosis and endometriosis increases relapse risk 3, 6, 7 . Our mutational characterization suggests that both of these disorders originate from NE, raising the concern that patients receiving uterus-sparing cytoreductive surgery face a significant relapse risk. Over the past decade, DNG has proven effective for treatment of endometriosis and has been approved for such. However, DNG has also been used for treatment of adenomyosis-related symptoms 26, 30 , despite a lack of formal knowledge of its side-effects and efficacy in this context. Indeed, efficacy of DNG in treating adenomyosis reportedly varies by individual, in contrast to treatment with GnRHa 34, 35 . Although DNG potentially has the advantages of relatively longterm efficacy and oral administration, there is currently no proper therapeutic management protocol for its use in treating adenomyosis 16 . Our work using an immortalized cell system in vitro has suggested that adenomyotic lesions frequently contain KRAS mutations that may epigenetically downregulate PR and thus reduce DNG efficacy. This observation should be followed up in a large number of DNG-treated adenomyosis patients to determine if our hypothesis is valid and if its implications are translatable to the clinic.
In our cohort of adenomyosis patients, pretreatment with LNG-IUS, an intrauterine device producing local progestin, showed no outcome correlation with the presence of KRAS mutations ( Table 1 ). We speculate that this discrepancy could be due to differences in the effective concentration of progestin delivered to the uterus by local (LNG-IUS) vs. oral (DNG) administration. It may also be relevant that only three LNG-IUS patients were available for our analysis. In any case, at least for oral DNG therapy, KRAS status may be a biomarker of treatment efficacy, and testing a needle biopsy of an adenomyosis lesion for KRAS mutation and/or PR expression might be a valuable diagnostic option. Obviously, further investigations are required to establish the validity of this approach, but investigation of the KRAS and PIK3CA mutation status of non-diseased uterine tissue of adenomyosis patients might greatly aid in surgical decisionmaking and therapeutic management. The establishment of this cell line was approved by the Ethics Committees of the National Cancer Center and Nagoya University, and the subject gave informed consent for the use of her clinical samples. Tissue samples from patients with adenomyosis were obtained at the University of Tokyo Hospital and Juntendo University Hospital between December 2016 and July 2019. All patients underwent magnetic resonance imaging for diagnostic purposes. Adjacent normal tissues, which were grossly and tactically distinguishable from adenomyotic lesions, were collected during surgery. Histological review by the study pathologist confirmed that there was no significant contamination of normal tissue by adenomyotic cells. See also Supplementary Data 1 and 2 , and 22-24 for additional clinical details pertaining to these specimens.
With respect to therapies, prior to surgery, patients with adenomyosis underwent treatment with GnRHa, DNG, or LNG-IUS according to their Fig. 7 , LNG-IUS levonorgestrelreleasing intrauterine systems symptoms. GnRHa was mainly used to improve blood hemoglobin levels in patients with severe anemia due to heavy menstrual bleeding (HMB). For GnRHa treatment, subcutaneous injection of 1.88 mg leuprorelin acetate or 1.8 mg goserelin acetate was initiated during menstruation and repeated every 4 weeks. DNG was used to relieve symptoms in patients with dysmenorrhea alone, whereas LNG-IUS was used for those with dysmenorrhea and HMB. For DNG, daily oral administration of 2 mg was started on days 2-5 of menstruation. For LNG-IUS, 52 mg LNG was inserted into the uterine cavity on day 7 of menstruation.
Next-generation sequencing analyses. Lesions and adjacent normal tissues were obtained from surgically resected specimens, immediately frozen after resection (fresh-frozen), and stored at −80°C. Samples of peripheral blood and/or monocytes from ascites fluid were stored at −30°C. See Supplementary Data 3 for additional sample information. Genomic DNA was extracted from specimens using the QIAamp DNA Blood Midi Kit or the QIAamp Fast DNA Tissue Kit (Qiagen) and quantified by Nanodrop (Thermo Fisher). Fragmentation of genomic DNA was performed using a Covaris LE220 sonicator to produce fragments of~200 bp and sequencing libraries were generated using the NEBNext Ultra DNA Library Prep kit for Illumina (New England BioLabs). Exonic fragments were enriched with the SureSelect Human All Exon Kit v6 (Agilent Technologies) and paired-end libraries were analyzed and quantified using 2200Tapestation (Agilent Technologies) and a Qubit Fluorometer (Invitrogen). Massively parallel, paired-end sequencing of sample libraries was performed with a HiSeq2500 sequencer (Illumina) as previously described 36 (Supplementary Data 4) .
WES reads were independently aligned to the human reference genome (hg38) using BWA, Bowtie2 (http://bowtie-bio.sourceforge.net/bowtie2/index.shtml), and NovoAlign (http://www.novocraft.com/products/novoalign/). Both somatic synonymous and non-synonymous mutations were called using three publicly available mutation callers: MuTect (http://www.broadinstitute.org/cancer/cga/ mutect), SomaticIndelDetector (http://www.broadinstitute.org/cancer/cga/node/ 87), and VarScan (http://varscan.sourceforge.net). Mutations were discarded if any of the following criteria were met: the total read number was <100, the mutant read number was <7, the VAF in disease samples was <0.024, the VAF in the germline control samples was >0.01, the mutation occurred in only one strand of the genome, or the variant was present in normal human genomes in either the 1000 Genomes Project dataset (http://www.internationalgenome.org/) or our in-house database. Gene mutations were annotated by SnpEff (http://snpeff.sourceforge.net). To this end, genomic DNA samples from adenomyosis tissues and corresponding germline controls were subjected to TDS (see details below). Over 100 targets were evaluated in this validation experiment, allowing us to establish criteria that Supplementary Fig. 3 ).
Validation of single-nucleotide variations by TDS. Genomic regions (~250 bp) containing candidate mutated bases were PCR-amplified using appropriate primer sets (Supplementary Data 5). PCR products were purified using AMPure beads (Beckman) and subjected to library construction using the NEBNext Ultra DNA Library Prep Kit for Illumina (New England BioLabs). Libraries were sequenced on an Illumina Miseq using Reagent Kit V2 (300 cycles) to generate 150 bp pairedend reads.
As the VAF values of the observed mutations in adenomyosis were quite low, we performed a statistical calculation to determine whether these alterations were true somatic mutations or NGS noise. In general, it is expected that the distribution of the difference in VAFs between lesion and control samples follows a normal distribution. For each position i, a difference of VAFs between adjacent (a) and normal (n) is defined by d i ¼ max y2Σ ja y;i À n y;i , where Σ is the set of nucleotides A; C; G; T f g . Let μ j and σ j be the mean (shown in column M in Supplementary Data 12 and column L in Supplementary Data 14-20 and 28-29) and the SD (shown in column N in Supplementary Data 12 and column M in Supplementary Data 14-20 and 28-29), respectively, of the set d k jk ¼ j À K; ; j À 1; j þ 1;
; j þ K f g for the estimated position j. If one assumes that X $ Nðμ j ; σ 2 j Þ, then the somatic mutation rate for j is defined by P X>d j <0:05, d j >0:001 and n y;j <0:01, where y 2 Σ. (Qiagen) and quantified by Qubit fluorometer (Thermo Fisher). TDS analyses were described above. See Supplementary Data 23 for patient and sample information.
As peripheral blood samples were not available for the FFPE tissue samples, we had to use histologically normal (NM) tissue samples as a negative control. Most SNVs, including KRAS and PIK3CA mutations, were only detected in NE but not NM (Fig. 2-4 and Supplementary Data 14-21). As the VAFs of the mutations in the macro-dissected epithelial component of NE were low (Fig. 5b) , we considered an alteration in a sample as a true mutation if its VAF was higher than the mean VAF + 3 SD in the 56 NE samples (Supplementary Data 26) . The cutoffs for the SNV are as follows: 0.335% (mean: 0.065%, SD: 0.09%) for KRAS p.G12/G13, 0.302% (mean: 0.05%, SD: 0.084%) for KRAS p.Q61, 0.127% (mean: 0.043%, SD: 0.028%) for PIK3CA p.E542E545, 0.158% (mean: 0.032%, SD: 0.042%) for PIK3CA p. H1047, and 0.15% (mean: 0.042%, SD: 0.036%) for PPP2R1A p.R179-R183.
Immunohistochemistry. Adenomyosis samples were fixed in 4% paraformaldehyde (Pierce) at 4°C for 24 h. Paraffin sections (5 μm) were subjected to immunostaining with anti-progesterone receptor antibody (undiluted; clone: 1E2; Ventana) using the Benchmark XT automated staining system (Roche). Scoring of all PR immunostaining was performed blind by T.H.Y. to avoid evaluator bias.
Bisulfite sequencing. Genomic DNA from LCM-enriched adenomyotic lesions was subjected to bisulfite conversion using an EpiTect Bisulfite Kit (Qiagen). Converted DNA samples were amplified by PCR using a Kapa HiFi Uracil + Kit (Kapa Biosystems). All procedures were performed according to the manufacturer's instructions. The bisulfite converted genomic DNA were subjected to the PCR; 98°C for 5 min followed by 50 cycles of 98°C for 10 s, 60°C for 10 s, and 72 for 30 s. The primer sequences used for PCR were as follows 6, 37 .
PR-A forward, 5′-GGTTTTGTTAGGGATAGGATTTTTT-3′; PR-A reverse, 5′-ACTACCTCCAACACCCCTTATAACT-3′; PR-B forward-1, 5′-TGTGGGTGGTATTTTTAATGAGA -3′; PR-B reverse-1, 5′-CCCCCTCACTAAAACCCTAAA-3′; PR-B forward-2, 5′-AGTATGGAGTTAGTAGAAGTT-3′; PR-B reverse-2, 5′-TCACAAGTCCAACACTTAAATAACT-3′.
PCR products were purified using AMPure beads (Beckman) and subjected to library construction using the NEBNext Ultra DNA Library Prep Kit for Illumina (New England BioLabs). Libraries were sequenced on an Illumina Miseq using Reagent Kit V2 (300 cycles)(Illumina) to generate 150 bp paired-end reads.
Immortalized epithelial endometrial cells. To generate immortalized human endometrial cells, normal endometrial cells obtained from a patient (41 years old) with cervical squamous cell carcinoma were cultivated in Advanced DMEM: F12 (Invitrogen) containing 100 ng/ml EGF (Sigma), 10 μM Y-27632 (Selleck Chemcals), 2% B-27 (Thermo Fisher Scientific), and 10 nM 17β-estradiol (Calbiochem). Lentiviral vectors expressing TERT, cyclin D1, and mutant CDK4 (CDK4 R24C : an inhibitor-resistant form of CDK4) were constructed by recombination with a lentiviral vector, CSII-CMV-RfA (a kind gift from Dr. Hiroyuki Miyoshi). To obtain infectious lentiviral particles, 293T cells (ATCC) were transfected with indicated constructs and packaging plasmids (pCAG-HIVgp and pCMV-VSV-G-RSV-Rev) (kind gifts from Dr Hiroyuki Miyoshi). For immortalization, the normal endometrial cells were transduced with mutant CDK4 (CDK4 R24C ), cyclin D1, and TERT via lentivirus-mediated gene transfer. The immortalized cells were seeded in the matrigel (Rensselaer)-coated six-well plates. Human embryonic kidney 293T cells (ATCC) were cultured in DMEM-F12 containing 10% fetal calf serum (Life Technologies). The 293T cells (5 × 10 6 cells) were plated in a 10 cm dish, incubated for 24 h, and then transfected with 1 μg of the retroviral plasmids (HA-tagged wild-type or mutant KRAS (G12C or G12D) (Addgene; catalog number 75282, 58901, and 58902) or PIK3CA (cloned cDNA subcloned into pBabe backbone vector) with ecotropic packaging plasmids (Takara Bio) for 24 h using Lipofectamine LTX (Thermo Fisher). After 24 h, the virus-containing medium was filtered (0.45 μm filter, Millipore) and supplemented with 4 μg/ml polybrene (Nacalai). For retroviral gene transductions, the culture medium was replaced by the appropriate retroviral supernatant (1:4 dilutions) and incubated at 37°C. Transduced immortalized cells were cultured with DNG (Sigma) at 37°C, followed by counting of cell numbers using a Countess II cell counter (Invitrogen). For cell cycle analyses, BrdU incorporation was performed using the APC-BrdU kit (BD Pharmingen) and measured by FACs Canto II (BD Biosciences). 
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